Axsome Therapeutics, Inc. · NASDAQ:AXSM
Axsome Therapeutics — ASCP 2019 Oral Session
17 slides from Axsome Therapeutics's conference presentation, May 2019
Slide 1: Efficacy and Safety of AXS-05 in Major Depressive Disorder: Phase 2 Trial Results
Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results of a Phase 2, Double-Blind, Active-Controlled Trial ASCP 2019 Oral Session Cedric O’Gorman4, Ashley Anderson4, Dan V. Iosifescu1,2, Mark Jacobson4, Amanda Jones4, Kellie Ke
Slide 2: New Agents Needed for Treatment of MDD
ASCP 2019 New Agents Needed for Treatment of MDD • Major depressive disorder (MDD) is a disabling, chronic and prevalent condition.1 MDD is the leading cause of suicide in the U.S.2 • 63% and 44% of MDD patients have inadequate response to initial therapy and second line therapy, respectively.1 • Cu
Slide 3: Glutamatergic Signaling in MDD: Potential Role for NMDA Blockade
ASCP 2019 Glutamatergic Signaling in MDD: Potential Role for NMDA Blockade • Clinical and preclinical evidence has implicated dysfunctional glutamatergic neurotransmission in the pathophysiology of MDD, suggesting a role for NMDA receptor antagonism in the treatment of MDD.1,2 • NMDA receptor blocka
Slide 4: AXS-05: Novel, Oral, NMDA Receptor Antagonist with Multimodal Activity
ASCP 2019 AXS-05: Novel, Oral, NMDA Receptor Antagonist with Multimodal Activity AXS-05 (DM + BUP) • NMDA receptor antagonism – DM component of AXS-05 NMDA • Sigma-1 receptor agonism – DM component of AXS-05 • Triple-reuptake inhibition (serotonin, norepinephrine, dopamine) σ1 – DM and bupropion com
Slide 5: AXS-05 vs Ketamine: Receptor Binding and Activity
ASCP 2019 AXS-05: Novel, Oral, NMDA Receptor Antagonist with Multimodal Activity Comparison of Receptor Binding and Activity for AXS-05 and Ketamine AXS-05 Ketamine1 (DM + BUP) NMDA NMDA σ1 SERT σ1 SERT DA NET NET DM Ketamine Assay • Rat cerebellar granule NMDA receptor binding (IC50) 402 nM 1047 nM
Slide 6: ASCEND Trial of AXS-05 in MDD: Design Summary
ASCP 2019 ASCEND Trial of AXS-05 in MDD: Design Summary ASCEND (Assessing Clinical Episodes in Depression) Trial Double-blind Dosing Period (6 weeks) Week 0 Week 1 Week 2 Week 3 Week 4 Week 6 Up to 4-week Screening Period N = 80 N = 43 AXS-05 Subjects with a (45 mg DM + 105 mg BUP) 1:1 randomization
Slide 7: ASCEND Trial of AXS-05 in MDD: Key Entry Criteria
ASCP 2019 ASCEND Trial of AXS-05 in MDD: Key Entry Criteria Inclusion criteria included: • Male or female 18-65 years of age inclusive • DSM-5 criteria for current MDD without psychotic features • Montgomery-Åsberg Depression Rating Scale (MADRS) total score of ≥ 25 • CGI-S score of ≥ 4 at baseline
Slide 8: ASCEND Trial: Demographics and Baseline Characteristics
ASCP 2019 ASCEND Trial of AXS-05 in MDD: Demographics and Baseline Characteristics AXS-05 Bupropion (45 mg DM / 105 mg BUP) (105 mg) (n = 43) (n = 37) Demographics Age (years) 37.3 (11.94) 37.7 (11.85) Female Gender, n (%) 25 (58.1%) 26 (70.3%) Race, n (%) White 30 (69.8%) 20 (54.1%) Black or Africa
Slide 9: Improvement in MADRS Total Score with AXS-05: Primary Endpoint
ASCP 2019 Improvement in MADRS Total Score with AXS-05: Primary Endpoint 0 -2 AXS-05 Bupropion -4 Change from Baseline MADRS Total Score -6 -8 -10 P=0.169 -12 -14 -16 P=0.024 -18 P=0.003 -20 P=0.007 P=0.013 -22 Baseline 1 2 3 4 5 6 Week AXS-05 Bupropion P-Value Primary Endpoint Change in MADRS Total
Slide 10: Early and Sustained Remission with AXS-05
ASCP 2019 Early and Sustained Remission with AXS-05: MADRS ≤ 10 50% P=0.004 AXS-05 Bupropion 45% 47% P=0.022 Percent of Subjects Achieving Remission 40% 40% 35% P=0.005 30% P=0.004 (MADRS ≤ 10) 30% 25% 26% 20% 15% 16% 16% 10% P=0.184 5% 3% 5% 5% 0% 0% 1 2 3 4 6 Week © Axsome Therapeutics, Inc. 10
Slide 11: Improvement in MADRS-6 with AXS-05: Core Symptoms of Depression
ASCP 2019 Improvement in MADRS-6 with AXS-05: Core Symptoms of Depression P-values over Time for Improvement of AXS-05 over Bupropion on MADRS-6 Study Week P-value Week 1 0.162 Week 2 0.027 Week 3 0.003 Week 4 0.008 Week 6 0.007 • The MADRS-6 is the sum of six of the 10 MADRS items that have been de
Slide 12: Rapid and Sustained Effect: Clinical Global Improvement
ASCP 2019 Rapid and Sustained Effect with AXS-05: Clinical Global Improvement Clinical Global Improvement 80% 70% AXS-05 Bupropion P=0.051 Percentage of Subjects Improving on the CGI-I 60% 59% 50% 40% 30% P=0.045 20% 27% 18% 10% 3% 0% Week 1 Week 6 (Very much and much (Very much improved) improved)
Slide 13: Clinical Response on MADRS-6 (≥50% improvement)
ASCP 2019 Rapid and Sustained Effect with AXS-05: Clinical Response on MADRS-6 (≥ 50% improvement) 80% Percentage of Subjects Achieving AXS-05 Bupropion (≥ 50% MADRS-6 Improvement) 70% P=0.014 60% 63% 50% Response 40% 30% 35% P=0.044 20% 10% 16% 3% 0% Week 1 Week 6 • As early as Week 1, AXS-05 resul
Slide 14: Remission (MADRS ≤ 12)
ASCP 2019 Rapid and Sustained Effect with AXS-05: Remission (MADRS ≤ 12) Achievement of Remission Using MADRS Total Score ≤ 12 70% AXS-05 Bupropion 60% P=0.032 Percent of Subjects Achieving Remission (MADRS ≤ 12) 50% 54% 40% 30% 30% 20% P=0.057 10% 9% 0% 0% Week 1 Week 6 • Remission may be defined b
Slide 15: ASCEND Trial Results: Safety & Tolerability
ASCP 2019 ASCEND Trial Results: Safety & Tolerability • AXS-05 was safe and well tolerated in this trial with similar overall rates of adverse events being reported in both treatment arms. • There were no reported serious adverse events. • The most commonly reported adverse events in the AXS-05 arm
Slide 16: ASCEND Trial of AXS-05 in MDD: Conclusions
ASCP 2019 ASCEND Trial of AXS-05 in MDD: Conclusions • AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity, representing a potential mechanistically new approach for the treatment of depression. • Treatment with AXS-05 in this trial resulted in rapid, substanti
Slide 17: Q&A
Q&A © Axsome Therapeutics, Inc. 17